Hib-DTaP-poliovirus vaccine - Sanofi
Alternative Names: DPT-IPV/Hib vaccine - Sanofi; DTaP-IPV-Hib - sanofi; DTaP-Polio-Hib vaccine - Sanofi; Hib-DTP-acellular-poliovirus vaccine - sanofi; Japan Penta - sanofi; Pediacel; Pentacel; Pentaxim; SP 0204; VN 0105Latest Information Update: 04 Apr 2022
At a glance
- Originator sanofi pasteur
- Developer Sanofi; Sanofi Pasteur
- Class Bacterial vaccines; Haemophilus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 31 Mar 2021 Daiichi Sankyo terminates development agreement with Sanofi, for Hib-DTaP-poliovirus vaccine in Japan
- 07 Feb 2019 Sanofi announces intention to submit regulatory application for pediatric Diphtheria, Haemophilus infections, Pertussis, Poliomyelitis and Tetanus in Japan in 2023
- 31 Jul 2018 Sanofi announces intention to submit regulatory application for Diphtheria, Haemophilus infections, Pertussis, Poliomyelitis and Tetanus in Japan in 2019